trending Market Intelligence /marketintelligence/en/news-insights/trending/e1EjrimsPhdNg_G5T1qX3Q2 content esgSubNav
In This List

Ascletis Pharma appoints former Novartis executive as chief scientific officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Ascletis Pharma appoints former Novartis executive as chief scientific officer

Ascletis Pharma Inc. appointed Handan He, a former Novartis AG executive, as the company's chief scientific officer.

The new chief scientific officer will report to Ascletis Pharma Chairman and CEO Jinzi Wu. She was the global head of computational, biopharmaceutics and translational pharmacokinetics/pharmacodynamics at Novartis.

Over her 22-year tenure at Novartis, He authored more than 30 clinical trial applications and three new drug marketing applications.

Ascletis former chief medical officer Li Zhengqing left the company in July after joining less than six months ago. Former CFO Lindi Tan also departed the company on Sept. 30, after joining less than one year ago.